Mersana Therapeutics Inc (NASDAQ:MRSN) Expected to Announce Earnings of -$0.38 Per Share

Equities analysts forecast that Mersana Therapeutics Inc (NASDAQ:MRSN) will post earnings per share of ($0.38) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Mersana Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.41). Mersana Therapeutics posted earnings of ($0.97) per share in the same quarter last year, which indicates a positive year over year growth rate of 60.8%. The firm is scheduled to issue its next quarterly earnings results on Friday, March 13th.

According to Zacks, analysts expect that Mersana Therapeutics will report full-year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.72) to ($0.38). For the next year, analysts forecast that the business will report earnings of ($1.42) per share, with EPS estimates ranging from ($1.84) to ($1.21). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Mersana Therapeutics.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02. Mersana Therapeutics had a negative return on equity of 41.14% and a negative net margin of 79.49%. The business had revenue of $0.84 million for the quarter, compared to analysts’ expectations of $0.50 million.

Several research firms have weighed in on MRSN. Zacks Investment Research raised Mersana Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 23rd. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Mersana Therapeutics in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $7.83.

MRSN stock traded up $0.08 during midday trading on Monday, hitting $4.24. 495,890 shares of the stock were exchanged, compared to its average volume of 246,434. The stock’s 50-day moving average price is $2.58 and its 200-day moving average price is $3.03. The stock has a market cap of $203.03 million, a price-to-earnings ratio of -1.52 and a beta of 2.09. Mersana Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $7.65. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.12 and a current ratio of 5.12.

Several hedge funds and other institutional investors have recently made changes to their positions in MRSN. Marshall Wace LLP acquired a new stake in Mersana Therapeutics during the 1st quarter valued at $141,000. Acadian Asset Management LLC acquired a new position in shares of Mersana Therapeutics in the second quarter worth $204,000. Russell Investments Group Ltd. lifted its position in shares of Mersana Therapeutics by 41.8% in the second quarter. Russell Investments Group Ltd. now owns 13,900 shares of the company’s stock valued at $56,000 after acquiring an additional 4,100 shares in the last quarter. Panagora Asset Management Inc. purchased a new stake in shares of Mersana Therapeutics in the second quarter valued at $397,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Mersana Therapeutics by 144.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 85,045 shares of the company’s stock valued at $345,000 after acquiring an additional 50,195 shares during the last quarter. 80.37% of the stock is currently owned by institutional investors.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

Featured Article: Technical Indicators – What is a Golden Cross?

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.